Batavia Bioservices and UvA Holding Announce STEP™ Technology Exclusive License

LEIDEN, THE NETHERLANDS--(Marketwired - April 29, 2013) - Batavia Bioservices BV and UvA Holding BV announced today that they have successfully concluded an agreement granting Batavia Bioservices the exclusive rights to STEP™ technology developed by scientists at CellaGenics BV, an UvA Holding BV company.

Under the agreement, Batavia Bioservices has been granted the exclusive license to the STEP™ technology, a revolutionary, plasmid-based system that significantly reduces the time required to develop recombinant protein-producing mammalian cell lines while increasing protein production more then 10-fold.

Menzo Havenga (CEO Batavia Bioservices) commented: “We are very pleased that UvA Holding has selected Batavia Bioservices as its marketing partner for STEP™ technology since we firmly believe that this technology will significantly reduce manufacturing costs. Chris Yallop (COO Batavia Bioservices) added: “STEP™ technology also allows the development of so-called rare diseases biopharmaceutical products, which have always been considered too expensive to develop. Piet Scholten (Director UvA Holding BV) concluded: “With their in-depth know how in biopharm manufacturing, vast network, and presence in both Europe and USA, Batavia Bioservices provided the ideal landing platform for marketing our technology and we look forward to a fruitful relationship!”

Financial details of the exclusive license agreement were not disclosed

About Batavia Bioservices BV

Batavia Bioservices is a biopharmaceutical process & product development services company, dedicated to add value to its customers by providing high quality biopharmaceuticals for proof-of-concept studies as well as pre-clinical and clinical materials. The company, headquartered in Leiden the Netherlands has in-depth know how regarding manufacturing of recombinant proteins, antibodies and vaccines. For more information please visit us at www.Bataviabioservices.com.

About UvA Holding BV

UvA Holding is a private company and a 100% subsidiary of University of Amsterdam. The company develops, implements and manages market-oriented activities which are non-core but at the same time directly related to the university.

Batavia Bioservices and UvA Holding announce STEP technology exclusive:

http://hugin.info/148797/R/1696862/559014.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Batavia Bioservices B.V. via Thomson Reuters ONE

[HUG#1696862]